The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic factors in patients with nonmetastatic gastric cancer treated with contemporary multimodality strategies.
 
Ariceli Alfaro
No Relationships to Disclose
 
Tuyen Hoang
No Relationships to Disclose
 
Jasmine Huynh
No Relationships to Disclose
 
Jingran Ji
No Relationships to Disclose
 
Andrew H. Ko
Honoraria - Biomedical Learning Institute; Biomedical Learning Institute; Biomedical Learning Institute; Biomedical Learning Institute; Clinical Care Options; Clinical Care Options; Clinical Care Options; Clinical Care Options; Dava Oncology; Dava Oncology; Dava Oncology; Dava Oncology; Elsevier; Elsevier; Elsevier; Elsevier; MORE Health; MORE Health; MORE Health; MORE Health; OncLive; OncLive; OncLive; OncLive; Peerview; Peerview; Peerview; Peerview; Pharmatecture; Pharmatecture; Pharmatecture; Pharmatecture; Research to Practice; Research to Practice; Research to Practice; Research to Practice; Xcenda; Xcenda; Xcenda; Xcenda
Consulting or Advisory Role - ARMO Biosciences; ARMO Biosciences; ARMO Biosciences; ARMO Biosciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Celgene; Celgene; Celgene; Celgene; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; Imugene; Imugene; Imugene; Imugene; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; SynCoreBio; SynCoreBio; SynCoreBio; SynCoreBio; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics
Speakers' Bureau - Clinical Care Options; Clinical Care Options; Clinical Care Options; Clinical Care Options
Research Funding - AbGenomics International (Inst); AbGenomics International (Inst); AbGenomics International (Inst); AbGenomics International (Inst); Apexigen (Inst); Apexigen (Inst); Apexigen (Inst); Apexigen (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); TwoPoreGuys/Ontera (Inst); TwoPoreGuys/Ontera (Inst); TwoPoreGuys/Ontera (Inst); TwoPoreGuys/Ontera (Inst)
 
May Thet Cho
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
 
Darryl Hiyama
No Relationships to Disclose
 
Farshid Dayyani
Employment - Roche (I); Roche (I); Roche (I); Roche (I)
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; ipsen; ipsen; ipsen; ipsen; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)